Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Meiji Launches Rezurock in Thailand
Meiji Seika Pharma said on April 2 that it has launched its selective ROCK2 inhibitor Rezurock (belumosudil) in Thailand for the treatment of chronic graft-versus-host disease (cGVHD). The drug will be marketed by Meiji’s local subsidiary in partnership with Romeck…
To read the full story
BUSINESS
- Takeda Commits Up to US$30 Million to Indonesia Plasma Partnership
July 14, 2026
- FDA Greenlights Leqembi Iqlik for Alzheimer’s Initiation Therapy
July 14, 2026
- Padcev/Keytruda Bags Expanded US Nod in Perioperative MIBC
July 14, 2026
- Olumiant Oral Suspension Now Available in Japan: Lilly/Incyte
July 14, 2026
- Japan Pharma Market Grows 3.8% in FY2025 as Protected Brands Shine: IQVIA
July 13, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…